{"id":"sublingual-sufentanil","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1201163","moleculeType":"Small molecule","molecularWeight":"578.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sufentanil activates mu-opioid receptors, which modulate pain perception and emotional response to pain. The sublingual formulation allows rapid absorption through the oral mucosa, bypassing first-pass hepatic metabolism and enabling faster onset of action compared to oral opioids. This formulation is designed for acute pain management with quick onset kinetics.","oneSentence":"Sublingual sufentanil is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to produce rapid analgesia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:53.427Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain management in opioid-tolerant patients"},{"name":"Breakthrough pain in opioid-tolerant patients"}]},"trialDetails":[{"nctId":"NCT04959812","phase":"PHASE1, PHASE2","title":"Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-03-01","conditions":"Healthy","enrollment":46},{"nctId":"NCT05288348","phase":"PHASE3","title":"DSUVIA Early Evaluation of Pain Trial","status":"COMPLETED","sponsor":"Frank Guyette","startDate":"2022-08-05","conditions":"Traumatic Injury","enrollment":150},{"nctId":"NCT06917651","phase":"PHASE3","title":"Management of Moderate to Severe Monotraumatic Pain With Sublingual Sufentanil in an Emergency Situation.","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-04-22","conditions":"Pain Management","enrollment":300},{"nctId":"NCT04263909","phase":"PHASE4","title":"The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-01","conditions":"Spine Fusion, Pain, Postoperative, Opioid Use","enrollment":199},{"nctId":"NCT04561375","phase":"PHASE4","title":"Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-12-11","conditions":"Knee Arthroscopy","enrollment":61},{"nctId":"NCT04716413","phase":"PHASE4","title":"Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2021-09-27","conditions":"Acute Pain","enrollment":3},{"nctId":"NCT03882320","phase":"NA","title":"Medico-economic Evaluation of Sublingual PCA (Zalviso) Versus Oxycodone-PCA in the Management of Postoperative Pain.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2019-03-01","conditions":"Analgesia","enrollment":60},{"nctId":"NCT04432428","phase":"PHASE4","title":"Safety and Efficacy of Patient Controlled Analgesia Using the Sublingual Sufentanil Tablet System (SSTS) in a Fast Track Rehabilitation Program After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-05-26","conditions":"Postoperative Pain","enrollment":90},{"nctId":"NCT03373851","phase":"","title":"Sublingual Sufentanil PCA Usability for Postoperative Pain (Zalviso® System)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-06-25","conditions":"Trauma, Surgery","enrollment":119},{"nctId":"NCT04387136","phase":"PHASE4","title":"Intraoperative Sublingual Sufentanil for Acute Pain in the Ambulatory Surgery Center","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-10-14","conditions":"Pain, Pain, Acute, Anesthesia","enrollment":53},{"nctId":"NCT05388188","phase":"","title":"DSUVIA in Patients With SCD VOC Present in the ED","status":"UNKNOWN","sponsor":"Jason Wilson","startDate":"2022-03-30","conditions":"Sickle-Cell Disease With Crisis","enrollment":100},{"nctId":"NCT05307341","phase":"PHASE4","title":"Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA)","status":"UNKNOWN","sponsor":"More Foundation","startDate":"2022-03","conditions":"Pain","enrollment":100},{"nctId":"NCT05259098","phase":"PHASE4","title":"Morphine vs Sufentanil PCA: Same Same or Different?","status":"COMPLETED","sponsor":"Hospital Central do Funchal","startDate":"2019-10-01","conditions":"Analgesia, Post Operative Pain, Patient Satisfaction","enrollment":54},{"nctId":"NCT04177862","phase":"PHASE4","title":"Sublingual Sufentanil vs Intravenous Fentanyl for Acute Pain in the Ambulatory Surgery Center","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2019-12-11","conditions":"Pain, Pain, Acute, Anesthesia","enrollment":75},{"nctId":"NCT04448457","phase":"NA","title":"Sufentanil Sublingual Tablet System for Postoperative Pain Management After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Tivoli","startDate":"2017-09-01","conditions":"Postoperative Pain","enrollment":72},{"nctId":"NCT03036514","phase":"NA","title":"Sublingual Sufentanil Tablet System (SSTS) Versus Intravenous Patient Controlled Analgesia After Back Surgery.","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2017-04-05","conditions":"Pain, Postoperative","enrollment":27},{"nctId":"NCT03403842","phase":"NA","title":"Acute Post-operative Pain in Colon Resections","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2018-02-01","conditions":"Analgesia","enrollment":159},{"nctId":"NCT02662764","phase":"PHASE3","title":"Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2016-09-28","conditions":"Moderate-to-severe Acute Pain","enrollment":320},{"nctId":"NCT02082236","phase":"PHASE1","title":"Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2014-05","conditions":"Healthy","enrollment":40},{"nctId":"NCT03355352","phase":"","title":"Observational Study of Analgesia and Cost-efficiency of Analgetic Medication Pumps (Zalviso and PCA-syringe Pump (PCA=Patient Controlled Analgesia)) After Urogenital Intervention at the Clinical Daily Routine","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2017-11-01","conditions":"Analgesic Quality, Mobility","enrollment":100},{"nctId":"NCT02447848","phase":"PHASE3","title":"Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2015-10","conditions":"Moderate-to-severe Acute Pain","enrollment":76},{"nctId":"NCT02662556","phase":"PHASE3","title":"A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2016-03","conditions":"Acute Moderate-to-severe Pain","enrollment":140},{"nctId":"NCT02356588","phase":"PHASE3","title":"A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2015-02","conditions":"Post-Operative Pain","enrollment":161},{"nctId":"NCT01660763","phase":"PHASE3","title":"Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2012-08","conditions":"Post Operative Pain","enrollment":419},{"nctId":"NCT01539642","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2012-02","conditions":"Post-Operative Pain","enrollment":172},{"nctId":"NCT01639729","phase":"PHASE1","title":"Effect of Delivery Route on PK of Sufentanil NanoTab","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2012-07","conditions":"Pharmacokinetics","enrollment":25},{"nctId":"NCT01761565","phase":"PHASE1","title":"Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2013-01","conditions":"Plasma Concentrations","enrollment":40},{"nctId":"NCT00718081","phase":"PHASE2","title":"A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2008-08","conditions":"Major Upper or Lower Abdominal Surgery","enrollment":88},{"nctId":"NCT00833040","phase":"PHASE2","title":"A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2009-04","conditions":"Cancer, Pain","enrollment":34},{"nctId":"NCT00894699","phase":"PHASE2","title":"A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2009-06","conditions":"Sedation, Anxiety, Pain","enrollment":40},{"nctId":"NCT00612534","phase":"PHASE2","title":"A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2008-03","conditions":"Post Operative Pain","enrollment":94}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dsuvia Sublingual Product","Dsuvia","Sufenta"],"phase":"marketed","status":"active","brandName":"Sublingual Sufentanil","genericName":"Sublingual Sufentanil","companyName":"University of Minnesota","companyId":"university-of-minnesota","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sublingual sufentanil is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to produce rapid analgesia. Used for Acute pain management in opioid-tolerant patients, Breakthrough pain in opioid-tolerant patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}